![]() ![]() In addition, patients lived for about 7 months without their disease getting worse when they received the Tecentriq combination compared with 5.5 months without Tecentriq. Patients lived on average for 18.6 months when they were given Tecentriq with carboplatin plus nab-paclitaxel compared with 13.9 months when given the combination without Tecentriq. Overall, patients given Tecentriq with the other medicines lived for 19.8 months on average compared with 14.9 months for patients given the medicines without Tecentriq.Īnother study investigated the effect of Tecentriq in 679 previously untreated patients with non-small cell lung cancer (NSCLC) who did not have a type of cancer known as EGFR mutant or ALK-positive NSCLC. In another main study of 1,202 patients with advanced non-small cell lung cancer which has spread and who had not received chemotherapy before, patients given Tecentriq together with paclitaxel, carboplatin and bevacizumab (other cancer medicines) lived on average for 8.4 months without their disease getting worse while those given paclitaxel, carboplatin and bevacizumab lived on average for 6.8 months without their disease getting worse. In a second study of 287 patients, patients on Tecentriq lived for 13 months on average compared with 10 months for patients on docetaxel. ![]() In one main study of 850 patients, those given Tecentriq lived for 14 months on average while those given docetaxel lived for 10 months. In patients with non-small cell lung cancer that is advanced or has spread, Tecentriq is more effective than docetaxel (another cancer medicine) at prolonging patients’ lives. Response was seen even in patients whose cancer cells did not produce much PD-L1. In another study involving 931 patients with urothelial cancer, those given Tecentriq lived slightly longer (8.6 months) than patients given chemotherapy (8 months) although the difference could be due to chance. In a study of 429 patients, the cancer shrank or was eliminated after Tecentriq treatment in 23% of patients who were not eligible for platinum chemotherapy and in 16% of patients who had previously had platinum chemotherapy. Tecentriq reduces tumours in patients with urothelial cancer that is advanced or has spread. ![]()
0 Comments
Leave a Reply. |